Voprosy onkologii · 2002
[Treatment of acute lymphoblastic leukemia in children according to the ALL-BFM-90m protocol in the Russian Federation and the Republic of Belarus].
Клиническое исследованиеСравнительное исследованиеАннотация на английскомСтатьяМногоцентровое исследованиеНазвание и аннотация: Оригинал на русском
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miakova N V, Aleĭnikova O V, Hartmann R, Rudneva A E, Trubina N M, Fechina L G, Timakov A M, Shamardina A V, Lebedev V V, Varfolomeeva S Iu, Dudkin S D, Dyshlevaia Z M, Timofeeva V N, Rumiantsev A G, Henze H, Karachunskiĭ A I
Аннотация
Prognosis for children treated according to the BFM-90m protocol (Berlin-Frankfurt-Munster Group) for acute lymphoblastic leukemia (ALL) improved significantly as compared with previous modalities. Methotrexate was used in the dose of 1,000 mg/m2, 36 h. The paper presents the 10-year results for this modification. Patients aged 0-15 years were treated at hematological hospitals of Moscow, other Russian towns and in Minsk, Belarus, (July 5, 1990-November 11, 2000). BFM-90m treatment was given to 682 children out of 1,326 with primary diagnosis of ALL; a comparative trial of the MB-91 protocol hed been carried out at the same clinics since 1991. During 10 years, recurrence-free survival was 72% while overall survival--77%. Toxicity of side-effects was tolerable. The BFM-90m treatment showed significantly better results in both countries.
Предметные рубрики MeSH
AdolescentAge FactorsAntimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsChi-Square DistributionChildChild, PreschoolData Interpretation, StatisticalFemaleFollow-Up StudiesHumansInfantInfant, NewbornLeucovorinMaleMethotrexatePrecursor Cell Lymphoblastic Leukemia-LymphomaPrognosisRepublic of BelarusRisk FactorsRussiaSex FactorsSurvival AnalysisTime Factors